Breaking Finance News

A statement released earlier today by H.C. Wainwright about Acceleron Pharma (NASDAQ:XLRN) bumps the target price to $57.00

In a report announced on 10/12/2017 H.C. Wainwright raised the target price of Acceleron Pharma (NASDAQ:XLRN) to $57.00 stating a potential upside of 0.47%.

Previously on 9/15/2017, RBC Capital released a statement about Acceleron Pharma (NASDAQ:XLRN) upped the target price from $0.00 to $44.00. At the time, this indicated a possible upside of 0.10%.

Yesterday Acceleron Pharma (NASDAQ:XLRN) traded -1.85% lower at $38.76. XLRN’s 50-day average is $37.48 and its two hundred day average is $32.05. With the last stock price close up 20.95% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time. 269,709 shares of the stock traded hands, down from an average trading volume of 426,994

See Chart Below

Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma has 52 week low of $23.07 and a one year high of $41.69 and has a market capitalization of $0.

A total of 9 equity analysts have released a ratings update on XLRN. Four analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average target price of $47.33.

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *